Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (113)

II-001Ruben Faelens

Predicting Clinical Efficacy Endpoints of a Nipocalimab Phase 3 Study with a Population PKPD Model Developed with Data from a Phase 2 Study in Generalized Myasthenia Gravis

Wednesday 15:30-17:00

II-002Undine Falkenhagen

qPnoMAD: A Residual-Trend-Based, ML-Guided Tool for Automated PopPK Model Development

Wednesday 15:30-17:00

II-003Xiaoqing Fan

Time-to-event analysis of iron homeostasis to inform survival in cancer patients

Wednesday 15:30-17:00

II-004Alan Faraj

Characterization of concizumab exposure and the link to free tissue factor pathway inhibitor, thrombin peak, and occurrence of bleeding events

Wednesday 15:30-17:00

II-005Lucie Fayette

Optimising covariate allocation at design stage using Fisher Information Matrix for Non-Linear Mixed Effects Models in pharmacometrics

Wednesday 15:30-17:00

II-006Elisa Fevola

A trimer-based MABEL approach for the First-In-Human starting dose selection of T-cell Engagers

Wednesday 15:30-17:00

II-007Angele Fleury

Deconvolution of Gastric Emptying based on interaction between Paracetamol and Liraglutide and its Extrapolation to Comedications using a PBPK Modeling approach

Wednesday 15:30-17:00

II-008Alex Foster-powell

Translatability of animal models for Alzheimer’s disease using a machine learning based workflow

Wednesday 15:30-17:00

II-009Masato Fukae

Assessment of the predictive performance of DeepNLME for a typical population pharmacokinetics: a simulation study and a case study with data from a first-in-human study of DS-8500

Wednesday 15:30-17:00

II-010Pablo Gamallo

Population PK/PD modelling and simulation for nedosiran dose guidance in children with primary hyperoxaluria type 1

Wednesday 15:30-17:00

II-011Mgambi Gideon Gamba

Investigating the hypothesis of lysosomal trapping of 1-hydroxymidazolam using PBPK modelling

Wednesday 15:30-17:00

II-012Peggy Gandia

Population pharmacokinetic modelling of amoxicillin concentrations in human breast milk – a contribution from the ConcePTION project

Wednesday 15:30-17:00

II-013Elena Garcia-Montoya

NfL concentration in CSF is a quantitative marker of the rate of neurodegeneration in aging and Huntington’s disease: a semi-mechanistic model-based analysis.

Wednesday 15:30-17:00

II-014Gastón García-Orueta

Optimal study design for pharmacokinetic modeling of teicoplanin, piperacillin and meropenem in critically ill children, including those undergoing Continuous Kidney Replacement Therapy

Wednesday 15:30-17:00

II-015Frédéric Gaspar

Beyond Genotype: The Added Value of CYP2C19 Phenotype on clopidogrel plasma concentrations in a hospitalized cohort using Pharmacokinetic Modeling

Wednesday 15:30-17:00

II-016Matteo Gazzin

InSilicoTrials’ Clinical Trial Simulator for Optimizing Oncology Study Designs, Trastuzumab Emtansine (T-DM1) Adaptive Dosing Case Example

Wednesday 15:30-17:00

II-017Dr Shadi Ghiasi

Artificial intelligence-based flare prediction in patients with Systemic Lupus Erythematosus (SLE): leveraging seven SLE clinical trial data from TransCelerate.

Wednesday 15:30-17:00

II-018Asina Gijasi

Predicting later-phase clinical trial efficacy in tuberculosis through back-translational modeling of rifapentine-containing regimens

Wednesday 15:30-17:00

II-019Anaïs Glatard

Expediting MIDD evidence generation to support quizartinib approval in newly diagnosed AML patients.

Wednesday 15:30-17:00

II-020Daniel Glazar

Patient-reported outcomes to inform patient-specific tumor growth inhibition parameters

Wednesday 15:30-17:00

II-021Nele Goeyvaerts

Viral kinetic modeling of mosnodenvir prophylaxis against DENV-3 in a controlled human infection model

Wednesday 15:30-17:00

II-022Janice Goh

An in vitro to in vivo translational framework for the prediction of drug efficacy in preclinical cell line derived xenografts

Wednesday 15:30-17:00

II-023Mikel Gomes

Predicting long-term weight loss using self-reported, digitally collected, real-world data after initiation of semaglutide for overweight/obesity

Wednesday 15:30-17:00

II-024Sebastiaan Goulooze

Causal mediation analysis in a pharmacometrics context

Wednesday 15:30-17:00

II-025Grace Shalom Govere

The use of modeling and simulation to inform Haemoglobinopathies drug development– a review of Scientific Advices from January 2014 to December 2024

Wednesday 15:30-17:00

II-026Gordon Graham

Continuous-time Markov models: Investigation into the use of Stan and msm for fitting disease progression models for EDSS in multiple sclerosis

Wednesday 15:30-17:00

II-027Sandra Grañana Castillo

Comparison of Body Weight and Body Surface Area-Based Dosing in Paediatric Population using PBPK modelling

Wednesday 15:30-17:00

II-028Silvia Grandoni

A translational whole-body PBPK modelling framework to support the development of locally acting orally inhaled compounds

Wednesday 15:30-17:00

II-029Nicolas Grégoire

Simulation-based prediction of pharmacokinetic/pharmacodynamic (PK/PD) index for Linezolid to treat cerebral infections in critically ill patients

Wednesday 15:30-17:00

II-030Boris Grinshpun

Simulation with Parameter Uncertainty using NMsim

Wednesday 15:30-17:00

II-031Meng Gu

Collateral sensitivity-driven dosing strategies in bacteriophage-antibiotic combination therapy: a mechanism-based approach

Wednesday 15:30-17:00

II-032Gustavo Guerrero

Model-Based Analysis of RO7589831 Mechanisms of Action in a MSI Cell Line

Wednesday 15:30-17:00

II-033Mariana Guimaraes

Application of High-Throughput PBPK Modeling to Develop an IVIVE Approach for Oral Permeability

Wednesday 15:30-17:00

II-034Yuchen Guo

Joint distribution modelling of drug metabolizing enzymes and transporters expression for PBPK-driven virtual patient simulation

Wednesday 15:30-17:00

II-035Nadja Haas

Comparison of different minimal continuous-time Markov model (mCTMM) structures for the analysis of symptom burden during anti-cancer drug therapy

Wednesday 15:30-17:00

II-036Helene Haguet

Use of modeling and simulation to inform the development of monoclonal antibodies to treat moderate-to-severe asthma: a review of EMA centralized procedure from 2014 to 2024.

Wednesday 15:30-17:00

II-037Alzahra Hamdan

Item Response Theory Modeling of Digital-Motor Measures as the Primary Outcomes of Rare Degenerative Ataxias

Wednesday 15:30-17:00

II-038Lisa Hanquet

Model informed drug development and CAR-T cells : A review of their use and credibility assessment in the context of EMA centralized procedures

Wednesday 15:30-17:00

II-039Miriam Stephanie Rosemarie Happ

The impact of bacterial growth kinetics on predicted antibiotic efficacy under different pharmacodynamic model assumptions: An in vivo case example

Wednesday 15:30-17:00

II-040Niklas Hartung

Physiologically-based toxicokinetic modelling of aluminium exposure in humans

Wednesday 15:30-17:00

II-042Bibi Hellinghus

Free IL-6 Following Treatment with Ziltivekimab in a Population with Moderate-to-Severe Chronic Kidney Disease

Wednesday 15:30-17:00

II-043Rasmus Henninger

Target site pharmacokinetics-pharmacodynamics of DNDI-6148 in a murine Leishmania major skin infection model: integrating parasite bioluminescent imaging and lesion dynamics

Wednesday 15:30-17:00

II-044Anneke Himstedt

Integrated human PK predictions: Beyond single parameters towards full profile benchmarking

Wednesday 15:30-17:00

II-045Christian Hollensen

Leveraging Model-Informed Drug Development to Expedite Phase 2b Initiation for an Oral Peptide Targeting PCSK9

Wednesday 15:30-17:00

II-046Ana Homšek

Estimation of infliximab clearance in patients with acute severe ulcerative colitis prior to and after achieving clinical remission using a population pharmacokinetic modelling approach

Wednesday 15:30-17:00

II-047Miao-Chan Huang

Physiologically-based pharmacokinetic modeling to predict systemic and liver exposure to bosentan

Wednesday 15:30-17:00

II-048Zhe Huang

A review of population pharmacokinetic/pharmacodynamic and exposure response modelling in three clinical pharmacology journals (2023-2025)

Wednesday 15:30-17:00

II-049Heinrich Huber

Can the PK drivers of anti-tumour response be xenograft specific

Wednesday 15:30-17:00

II-050Katrina Hui

Population pharmacokinetic (PPK) modeling analyses of tovorafenib in patients with RAF-altered, relapsed/refractory (r/r) pediatric low-grade glioma (pLGG), advanced solid tumors, and healthy adults

Wednesday 15:30-17:00

II-051Olga Ivanova

Analysis of Itacitinib effect on the biomarkers of inflammatory response in subjects with hematological malignancies treated with CAR-T therapy

Wednesday 15:30-17:00

II-052Ravi Kumar Jairam

Physiologically based ocular models for protein therapeutics in rabbits and monkeys

Wednesday 15:30-17:00

II-053Ludvig Jakobsson

A simulation-based evaluation of a hidden Markov model to characterize disease transitions using frequently sampled spirometry data

Wednesday 15:30-17:00

II-054Masoud Jamei

Volume of Distribution Covariates That You May not Have Considered!

Wednesday 15:30-17:00

II-055Candice Jamois

An Integrative Pharmacometric Approach Supports the Dose Selection Proposal of Englumafusp Alfa, a New Molecular Entity with No Single Agent Activity Developed in Combination

Wednesday 15:30-17:00

II-056Seongmee Jeong

Model-based dosage optimization of sirolimus for vascular anomalies on pediatrics

Wednesday 15:30-17:00

II-057Nicharee Jiracheep

Population Pharmacokinetics and Dose Optimization of a Novel Triple Combination Therapy: Arterolane-Piperaquine-Mefloquine in Kenyan Children with Malaria

Wednesday 15:30-17:00

II-058Tamara Jordens

PET-Guided Physiologically-Based Pharmacokinetic Modeling of tyrosine kinase inhibitors in NSCLC patients with brain metastases

Wednesday 15:30-17:00

II-059Tanvi Joshi

Extending a Quantitative Systems Pharmacology model of Ulcerative Colitis to a single all-comers Virtual Population for optimizing therapeutic combinations in Phase 3 trials.

Wednesday 15:30-17:00

II-060Felix Jost

It’s a match! Machine learning & compartmental modeling for early PK predictions

Wednesday 15:30-17:00

II-061Patrick Joyce

Investigating the Impact of the Binding Site Barrier on Antibodies: A Comparative Study of ODE and PDE Models

Wednesday 15:30-17:00

II-062Jie Ju

Using a smoother approach IMPRES-M to estimate parameters of biomarkers in multi-layered turnover networks

Wednesday 15:30-17:00

II-063Tobias Kanacher

Physiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcoma

Wednesday 15:30-17:00

II-064Evangelos Karakitsios

Extrapolation of Lung Pharmacokinetics from Preclinical Species and Implications for Dose Selection in Humans: the role of physiologically based pharmacokinetic modeling in the development of antitubercular drugs.

Wednesday 15:30-17:00

II-065Venetia Karamitsou

A pipeline for generating large virtual dog populations to predict preclinical drug-induced liver injury

Wednesday 15:30-17:00

II-066Mélanie Karlsen

PMX-CovEval: an open-source framework for robust and consistent evaluation of covariate model selection techniques

Wednesday 15:30-17:00

II-067Ronald Kadada Karyaburo

Towards the Best Practices to Create Virtual Healthy Control Populations for Organ Impairment Studies

Wednesday 15:30-17:00

II-068Csaba Katai

On the coupling between a basic FcRn mechanism and target-mediated drug disposition of antibodies—an asymptotic analysis in the high binding affinity limit

Wednesday 15:30-17:00

II-069Sonoko Kawakatsu

Population Pharmacokinetic Analysis of Tenofovir Alafenamide (TAF) and Tenofovir (TFV) in Adolescents and Children with HIV-1

Wednesday 15:30-17:00

II-070Aida Kawuma

Utilizing Typst and Quarto for Efficient Reporting in Pharmacometrics

Wednesday 15:30-17:00

II-071Ron Keizer

Retrospective design analysis to evaluate power for covariate selection from observational data

Wednesday 15:30-17:00

II-072Svenja Kemmer

Towards a translational QSP modeling approach to predict bone marrow toxicity

Wednesday 15:30-17:00

II-073Allan Kengo

Pharmacogenetics-guided isoniazid dosing in individuals with tuberculosis and HIV

Wednesday 15:30-17:00

II-074Feras Khalil

Allometric and Population pharmacokinetic Modeling for Human Dose Prediction in a First-in-Human Trial: A Case Study with Retrospective Evaluation

Wednesday 15:30-17:00

II-075Anisa Khan

Exploring the implications of poor acceptability on treatment adherence and response in children: an in-silico simulation study of deferasirox and amoxicillin

Wednesday 15:30-17:00

II-076Jonas Kildegaard

Dose selection of concizumab for prophylactic treatment of bleeding episodes in haemophilia A or B with or without inhibitors

Wednesday 15:30-17:00

II-077Peter Kilford

Development of network-based PBPK models to enhance the confidence in drug-drug interaction predictions

Wednesday 15:30-17:00

II-078Hyeonji Kim

Population Pharmacokinetic Modeling and Covariate Analysis of Lenalidomide in Renally Impaired Patients with Multiple Myeloma

Wednesday 15:30-17:00

II-079Hyun Chul Kim

Population pharmacokinetic-pharmacodynamic analysis of zolpidem to explore sex differences in healthy volunteers

Wednesday 15:30-17:00

II-080Yoonjin Kim

Pharmacokinetic Modeling of Enavogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Korean Healthy Volunteers and Patients with Type 2 Diabetes Mellitus

Wednesday 15:30-17:00

II-081Marian Klose

A Bayesian-NLME approach identifies patients at risk of delayed MTX elimination if informative TDM data is provided

Wednesday 15:30-17:00

II-082Kenneth Koh

Physiologically-based pharmacokinetic (PBPK) modelling for predicting drug-disease interactions: Suppression of CYP3A4 by interleukin-6 in cancer populations

Wednesday 15:30-17:00

II-083Jakob Kolar

Prediction of sildenafil concentrations in the central nervous system with physiologically based pharmacokinetic modelling

Wednesday 15:30-17:00

II-084Konstantina Koliopoulou

AutoML and Residual Error Meta-Modeling in Model-Informed Drug Development: A Case Study of Pharmaceutical Pellets.

Wednesday 15:30-17:00

II-085S.F. Koopman

Relationship between factor IX activity levels and bleeding in patients with haemophilia B on prophylaxis with an extended half-life factor IX concentrate (rIX-FP): A repeated time-to-event analysis.

Wednesday 15:30-17:00

II-086Luke Kosinski

Modeling Huntington’s disease progression using a bounded integer approach

Wednesday 15:30-17:00

II-087Vasiliki Kostiou

Mechanistic modelling of CAR T-cell therapy for multiple myeloma to assess multi-antigen targeting and identify factors associated with response.

Wednesday 15:30-17:00

II-088Marina Kotsiopoulou

Is flip-flop kinetics a myth?

Wednesday 15:30-17:00

II-089Elke Krekels

Changes in the relative contribution of hepatic metabolism and glomerular filtration to total plasma clearance in children younger than four years of age; when is scaling for the dominant elimination route in adults appropriate?

Wednesday 15:30-17:00

II-090Wojciech Krzyzanski

Cohort population estimates of covariance matrix for sparse pharmacokinetic data

Wednesday 15:30-17:00

II-091Victoria Kulesh

Healthy aging and Immunology: A Quantitative Model-Based Meta-Analysis (MBMA) of Age-Dependent Human T-Lymphocyte Homeostasis

Wednesday 15:30-17:00

II-092Karsten Kuritz

Efficient and Informed Model Development for NLME Models with Poor Parameter Identifiability

Wednesday 15:30-17:00

II-093Brigitte Lacroix

Exposure-response analysis of minzasolmin in Parkinson’s disease using a lean fit for purpose approach to inform decision making

Wednesday 15:30-17:00

II-094Pietro Laddomada

In vitro-in vivo differences in the relationship between cangrelor concentration and platelet aggregation inhibition effect: implications for the extrapolation of efficacy from adults and dose rationale for infants and children.

Wednesday 15:30-17:00

II-095Marie Lambert

Translational PK/PD modeling to support First-In-Human clinical trial of a MAT2A inhibitor

Wednesday 15:30-17:00

II-096Jennifer Lang

Evaluation of GalNAc-siRNA mediated reduction of ApoC3 and triglycerides in healthy participants using a population PK/PD approach

Wednesday 15:30-17:00

II-097Jurgen Langenhorst

Using Full Random Effects Models (FREM) in different software

Wednesday 15:30-17:00

II-098Anna Largajolli

Validating the D-RSC disease progression modelling framework for Duchenne muscular dystrophy and evaluating the long-term impact of givinostat therapy in pediatric patients

Wednesday 15:30-17:00

II-099Alexandra Lavalley-morelle

Efficient exposure-response analysis for time-to-event endpoints: beyond the use of time-static exposure metrics

Wednesday 15:30-17:00

II-100Félicien Le Louedec

Model-averaging, but not flattened priors, benefitted to the model-informed precision dosing of oral kinase inhibitors in oncology

Wednesday 15:30-17:00

II-101Albin Leding

Early phase 2a dose recommendation for 2nd generation diarylquinoline TBAJ-587

Wednesday 15:30-17:00

II-102Hyunjung Lee

PBPK Modeling Through Drug-Induced Liver Injury (DILI) Study by Nevirapine and Metabolite Concentrations in Liver Tissue and Blood

Wednesday 15:30-17:00

II-103Diane Lefaudeux

High-Throughput PBPK Framework in R using Open Systems Pharmacology Software for Anti-Tuberculosis Drug Development

Wednesday 15:30-17:00

II-104Apolline Lefevre

Trimeric Complexes: The key to optimizing T-cell Bispecifics (TCB) efficacy and safety

Wednesday 15:30-17:00

II-105Annabelle Lemenuel-diot

A novel mechanistic viral dynamics modeling (MVDM) framework to characterize the effect of combination therapies in chronic hepatitis B and evaluate the influence of individual characteristics in the Piranga phase 2 platform study

Wednesday 15:30-17:00

II-106Cristhyne Leon

Expansion of a mechanistic model of recurrent respiratory infections in children to the elderly and chronic obstructive pulmonary disease populations

Wednesday 15:30-17:00

II-108Raphaelle Lesage

Open-Source Quantitative Modeling of Tuberculosis Drug-Induced Cardiac Risks

Wednesday 15:30-17:00

II-109Karen Leys

Physiologically-based prediction of pharmacokinetics in neonates suffering perinatal asphyxia and undergoing therapeutic hypothermia – midazolam and its metabolites as case example

Wednesday 15:30-17:00

II-110Adéle L'Hostis

A Physiologically Based Pharmacokinetic Model for Cisplatin in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III

Wednesday 15:30-17:00

II-111Dr. Xia Li

Nipocalimab Effect on IgG Subclasses in Patients with Generalized Myasthenia Gravis (gMG)

Wednesday 15:30-17:00

II-112Yingxue Li

Mechanism-based Pharmacodynamic Model for the Hemodynamic effects of Norepinephrine in Healthy Volunteers

Wednesday 15:30-17:00

II-113Hyeongseok Lim

Population Pharmacokinetic and Pharmacodynamic modeling Analysis of rhIL-7-hyFc, a hybrid Fc-Fused Long-Acting Interleukin-7, to support Optimal Dose Regimens in Patients with Solid Cancer

Wednesday 15:30-17:00

II-114Yu-Jou Lin

An interactive pharmacokinetic, pharmacodynamic, and long-term outcome model framework to evaluate bedaquiline dose modifications in adults with tuberculosis

Wednesday 15:30-17:00

II-115Cathrine Lind

The Effect of Insulin, GLP-1 and GIP Receptor Agonists, and Sodium-Glucose Cotransporter 2 Inhibitor on Major Adverse Cardiovascular Events in Diabetic Patients

Wednesday 15:30-17:00